Acceleron blood disease drug hits goal in pivotal clinical trial
by Adam Feuerstein
Jun 28, 2018
1 minute
Acceleron Pharma said Thursday that its experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the blood disease myelodysplastic syndrome, meeting the primary goal of a Phase 3 clinical trial.
Based on the study
You’re reading a preview, subscribe to read more.
Start your free 30 days